Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing–remitting multiple sclerosis
- 199 Downloads
Fingolimod is the first oral drug approved for treatment of relapsing–remitting multiple sclerosis (RR-MS), and it has potential macular side effects. Despite the qualitative evidence of macular oedema under treatment, longitudinal quantitative assessment is lacking. To address this issue, we measured macular volume and central foveal thickness in a cohort of MS patients on fingolimod over 12 months of treatment.
Central foveal thickness (CFT) and total macular volume (TMV) were longitudinally recorded with spectral-domain optical coherence tomography in a cohort of 23 RR-MS patients treated with fingolimod at baseline, 3, 6 and 12 months. OCT parameters were analysed considering previous history of optic neuritis (ON). Comparison of means was performed with variance analysis (ANOVA).
Macular oedema occurred in none of the patients. Comparing both groups of patients (with and without previous ON), no statistically significant difference was found during the follow-up both for CFT and TMV (p = 0.99 and p = 0.96, respectively) although a slight early but not significant TMV reduction was detected.
In our cohort, therapy with fingolimod did not cause any change in CFT and TMV in MS patients during a 12-month follow-up independent of previous ON.
KeywordsMultiple sclerosis Optic neuritis Fingolimod Spectral-domain optical coherence tomography Central foveal thickness Total macular volume
Compliance with ethical standards
Conflict of interest
This is an independent work not supported by any sponsor. The authors have no financial interest regarding the content of this paper.
- 2.Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P for the FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New Engl J Med 362:387–401. https://doi.org/10.1056/NEJMoa0909494 CrossRefGoogle Scholar
- 3.Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, for the TRANSFORMS Study Group (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New Engl J Med 362:402–415. https://doi.org/10.1056/nejmoa0907839 CrossRefGoogle Scholar
- 11.Winges KM, Werner JS, Harvey DJ, Cello KE, Durbin MK, Balcer LJ, Calabresi PA, Keltner JL (2013) Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis. J Neuroophthalmol 33:322–329. https://doi.org/10.1097/WNO.0b013e31829c51f7 CrossRefGoogle Scholar